Hospital
Community Hospital South, INC.
Community Hospital South, INC. was paid $27.35M by Medicaid between Jan 2018 and Dec 2024, across 88 billing codes. Its largest line is 99284, emergency room visit (serious) — 42% of everything it billed.
33Billing provider infoCOMMUNITY HOSPITAL SOUTH, INC.
INDIANAPOLIS, IN 46227
INDIANAPOLIS, IN 46227
33aNPI1235109778assigned 01/26/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$27.35M
24GClaims424,631
24DCodes billed88
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Indiana
Rank by total paid#15 of 69
Median peer was paid$9.76M
This provider vs. median2.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 58,916 | $1.39M | |
| 2019 | 44,329 | $2.73M | |
| 2020 | 36,710 | $2.59M | |
| 2021 | 57,775 | $4.39M | |
| 2022 | 90,908 | $6.21M | |
| 2023 | 79,398 | $5.75M | |
| 2024incomplete | 56,595 | $4.28M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 42% | 78,838 | 66,540 | $11.62M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 44,565 | 39,492 | $6.56M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 5.7% | 23,265 | 18,212 | $1.55M |
| 71045 | Radiologic examination, chest; single view | 5.0% | 9,596 | 7,988 | $1.36M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.9% | 24,869 | 20,289 | $1.06M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 2,361 | 1,953 | $934K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.0% | 5,670 | 4,661 | $814K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 10,809 | 8,470 | $412K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.3% | 2,811 | 2,254 | $352K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 60,477 | 49,268 | $269K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,736 | 2,321 | $232K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,075 | 2,666 | $220K |
76 more codes
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,561 | $193K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,361 | $156K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 32,857 | $155K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,369 | $145K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,177 | $139K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,392 | $133K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 640 | $117K |
| 36415 | Collection of venous blood by venipuncture | <1% | 37,640 | $101K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 194 | $89K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 62 | $84K |
| 84484 | <1% | 7,930 | $55K | |
| 81025 | <1% | 9,490 | $51K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,258 | $50K |
| 43235 | <1% | 23 | $40K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 86 | $39K |
| 80053 | Comprehensive metabolic panel | <1% | 5,058 | $32K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 534 | $31K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 12 | $28K |
| 81001 | <1% | 14,967 | $27K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 465 | $25K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 621 | $24K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 112 | $22K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,176 | $22K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 101 | $21K |
| 83690 | <1% | 5,329 | $19K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 154 | $17K |
| 93017 | <1% | 126 | $17K | |
| 80076 | <1% | 3,286 | $17K | |
| 99221 | <1% | 68 | $15K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 361 | $13K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 414 | $13K |
| 99217 | <1% | 54 | $11K | |
| 87088 | <1% | 2,345 | $9K | |
| 87634 | <1% | 127 | $8K | |
| 80047 | <1% | 1,460 | $7K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 49 | $6K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 25 | $5K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 34 | $4K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 92 | $4K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 69 | $4K |
| 99218 | <1% | 18 | $3K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 41 | $3K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 242 | $3K |
| 85379 | <1% | 242 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 101 | $2K |
| 83880 | <1% | 75 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 152 | $977.46 |
| 82553 | <1% | 453 | $748.21 | |
| 88307 | <1% | 21 | $736.71 | |
| 81003 | <1% | 366 | $562.47 | |
| 85014 | <1% | 428 | $504.36 | |
| 87081 | <1% | 95 | $476.39 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 247 | $277.37 |
| 94799 | <1% | 15 | $196.40 | |
| 82565 | <1% | 32 | $139.78 | |
| 96376 | <1% | 87 | $73.71 | |
| 83735 | <1% | 30 | $43.32 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 43 | $35.33 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,477 | $29.91 |
| 85027 | <1% | 38 | $29.69 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,229 | $1.86 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 404 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 592 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 18 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 51 | $0.00 |
| C1769 | Guide wire | 0% | 13 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 23 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 31 | $0.00 |
| G0378 | Hospital observation service, per hour | 0% | 34 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 177 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 402 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 85 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 80 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 98 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 19 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMILLARD, HOLLY (SVP FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Community Health Network, INC | Indianapolis, IN | $161.73M |
| Community Health Network, INC | Indianapolis, IN | $32.97M |
| Community Hospital of Anderson & Madison County, INC | Anderson, IN | $32.30M |
| Fairbanks Hospital, INC. | Indianapolis, IN | $18.54M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.